5AM Ventures Closes Two Life Sciences Funds at $750 Million
Boston – April 14, 2022 – Cooley advised 5AM Ventures, a venture capital firm focused on building next-generation life sciences companies, on the close of 5AM Ventures VII, a $450 million early-stage venture capital fund, and 5AM Opportunities II, a $300 million later-stage fund, for a total of $750 million in committed capital. Partners Nicole Peppe and Jimmy Matteucci led the Cooley team advising 5AM Ventures.
The 5AM Ventures VII fund will be used to expand 5AM’s efforts to discover, incubate and invest in breakthrough life sciences companies, while the 5AM Opportunities II fund will invest in 5AM portfolio companies and non-5AM companies in the private and public markets.
“We are proud of the transformational impact that our companies can have on patient lives as they drive novel solutions to unmet medical needs,” Andrew Schwab, managing partner at 5AM Ventures alongside Kush Parmar, MD, PhD, said in a press release. “We are also grateful for the support of our existing and new investors, with over $2.2 billion raised for investments in innovative life science companies over our 20 years of continued growth.”
Founded in 2002 and based in San Francisco and Boston, 5AM Ventures has invested globally in 100+ public and private companies.
About Cooley LLP
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.
Cooley has 1,500 lawyers across 17 offices in the United States, Asia and Europe.